Table 1.
Baseline Characteristics of First-Episode Primary Psychotic Disorder (FEPP) and First-Episode Affective Psychotic Disorder (FEAP) Patients With Longitudinal Data Who are Eligible to Return to College
| FEPP | FEAP | Statistic | P-value | |
|---|---|---|---|---|
| Sample size (N = 88) | n = 43 | n = 45 | ||
| Age, mean ± SD (range), y | 20.3 ± 1.8 (18–25) | 20.4 ± 1.9 (18–26) | t = −0.365 | .716 |
| Female, no. (%) | 9 (21%) | 12 (27%) | χ 2 = 0.398 | .528 |
| Race, no. (%) | χ 2 = 1.346 | .510 | ||
| White | 32 (74%) | 34 (76%) | ||
| Black | 3 (7%) | 1 (2%) | ||
| American Indian | 0 (0%) | 0 (0%) | ||
| Asian/Pacific Islander | 5 (12%) | 7 (16%) | ||
| Missing | 3 (7%) | 3 (7%) | ||
| Marital status, no. (%) | - | - | ||
| Never married | 43 (100%) | 44 (98%) | ||
| Married/sep/divorced | 0 (0%) | 0 (0%) | ||
| Missing | 0 (0%) | 1 (2%) | ||
| In a romantic relationship, no. (%) | 4 (9%) | 9 (20%) | χ 2 = 2.015 | .156 |
| Missing | 6 (14%) | 6 (13%) | ||
| Living at home with parents, no. (%) | 40 (93%) | 37 (82%) | χ 2 = 0.268 | .604 |
| Living with a roommate(s), no. (%) | 2 (5%) | 3 (7%) | ||
| Missing | 1 (2%) | 5 (11%) | ||
| Referral source, no. (%) | χ 2 = 1.678 | .795 | ||
| Inpatient hospital | 24 (56%) | 28 (62%) | ||
| Partial hospital | 9 (21%) | 7 (16%) | ||
| Outpatient provider | 5 (12%) | 3 (7%) | ||
| Family | 2 (2%) | 4 (9%) | ||
| Other | 1 (2%) | 1 (2%) | ||
| Missing | 2 (5%) | 2 (4%) | ||
| No. of prior hospitalizations, mean ± SD (range) | 1.5 ± 0.8 (0–4) | 1.6 ± 0.8 (0–3) | t = −0.517 | .606 |
| >1 hospitalization, no. (%) | 15 (35%) | 20 (44%) | χ 2 = 0.839 | .360 |
| Hospitalization at McLean prior to OnTrack, no. (%) | 27 (62.8%) | 29 (64.4%) | χ 2 = 0.025 | .875 |
| No. of prior suicide attempts, mean ± SD (range) | 0.14 ± 0.41 (0–2) | 0.16 ± 0.57 (0–3) | t = −0.183 | .855 |
| Suicide attempts, any lifetime, no. (%) | 5 (12%) | 4 (9%) | χ 2 = 0.180 | .672 |
| Suicide attempts, prior 6 mo, no. (%) | 3 (7%) | 3 (7%) | χ 2 = 0.003 | .954 |
| No. of antipsychotic medication trials, mean ± SD | 1.9 ± 1.0 (1–5) | 1.7 ± 1.1 (1–6) | t = 0.684 | .496 |
| >1 antipsychotic medication trial, no. (%) | 22 (51%) | 20 (44%) | χ 2 = 0.447 | .504 |
| Missing | 3 (7%) | 3 (7%) | ||
| Co-occurring psychiatric disorders, any, no. (%) | 19 (44%) | 11 (24%) | χ 2 = 3.814 | .051 |
| Mood disorder, not otherwise specified | 1 (2%) | 0 (0%) | χ 2 = 1.059 | .304 |
| Attention deficit hyperactivity disorder | 4 (9%) | 2 (4%) | χ 2 = 0.817 | .366 |
| Substance use disorder | 14 (33%) | 8 (18%) | χ 2 = 2.562 | .109 |
| Generalized anxiety disorder | 0 (0%) | 0 (0%) | - | - |
| Panic disorder | 0 (0%) | 0 (0%) | - | - |
| Obsessive-compulsive disorder | 1 (2%) | 2 (4%) | χ 2 = 0.300 | .584 |
| Posttraumatic stress disorder | 1 (2%) | 0 (0%) | χ 2 = 1.059 | .304 |
| Eating disorder | 0 (0%) | 1 (2%) | χ 2 = 0.967 | .326 |
| Co-occurring medical disorders, any, no. (%) | 11 (26%) | 12 (27%) | χ 2 = 0.013 | .908 |
| Thyroid disorders | 1 (2%) | 1 (2%) | χ 2 = 0.001 | .974 |
| Obesity | 0 (0%) | 1 (2%) | χ 2 = 0.967 | .326 |
| Dyslipidemia | 1 (2%) | 0 (0%) | χ 2 = 1.059 | .304 |
| Head injury requiring medical eval/tx | 9 (21%) | 6 (13%) | χ 2 = 0.898 | .343 |
| Substance use, prior 6 mo, any, no. (%) | 25 (58%) | 34 (76%) | χ 2 = 3.287 | .070 |
| Cannabis use, prior 6 mo | 24 (56%) | 33 (73%) | χ 2 = 2.958 | .085 |
| Stimulant use, prior 6 mo | 2 (5%) | 2 (4%) | χ 2 = 0.002 | .963 |
| Cocaine use, prior 6 mo | 1 (2%) | 3 (7%) | χ 2 = 0.955 | .328 |
| Hallucinogen use, prior 6 mo | 8 (19%) | 4 (9%) | χ 2 = 1.763 | .184 |
| Opioid use, prior 6 mo | 0 (0%) | 0 (0%) | - | - |
| Inhalant use, prior 6 mo | 0 (0%) | 0 (0%) | - | - |
| PCP use, prior 6 mo | 0 (0%) | 0 (0%) | - | - |
| Missing | 2 (5%) | 2 (4%) | ||
| Lifetime history of substance use | 34 (79%) | 40 (89%) | χ 2 = 1.585 | .208 |
| Lifetime history of trauma, no. (%) | 10 (23%) | 15 (33%) | χ 2 = 1.274 | .259 |
| Physical abuse | 5 (12%) | 1 (2%) | χ 2 = 3.062 | .080 |
| Emotional abuse | 5 (12%) | 4 (9%) | χ 2 = 0.180 | .672 |
| Sexual abuse | 3 (7%) | 6 (13%) | χ 2 = 0.968 | .325 |
| Missing | 3 (7%) | 4 (9%) | ||
| FH of psychotic disorder in first degree relative | 2 (5%) | 6 (13%) | χ 2 = 1.649 | .199 |
| First degree relative with schizophrenia | 0 (0%) | 1 (2%) | χ 2 = 0.967 | .326 |
| First degree relative with bipolar disorder | 2 (5%) | 5 (11%) | χ 2 = 1.253 | .263 |
| FH of any psychiatric disorder in first deg. relative | 19 (44%) | 17 (38%) | χ 2 = 0.374 | .541 |
| FH of completed suicide | 5 (12%) | 7 (16%) | χ 2 = 0.288 | .591 |
| Any psychiatric symptoms at intake, no. (%) | 35 (81%) | 18 (40%) | χ 2 = 15.730 | <.0001 |
| Any psychotic symptoms at intake, no. (%) | 34 (79%) | 15 (33%) | χ 2 = 18.639 | <.0001 |
| Insight into mental illness at intake, no. (%) | 6 (14%) | 11 (24%) | χ 2 = 1.688 | .194 |
| Missing | 0 (0%) | 1 (2%) | ||
| Medication adherence, prior 6 mo | χ 2 = 0.447 | .800 | ||
| Adherent (>90%) | 18 (42%) | 24 (53%) | ||
| Inconsistent (10%–90%) | 3 (7%) | 6 (13%) | ||
| Nonadherence (<10%) | 3 (7%) | 4 (7%) | ||
| Missing | 19 (44%) | 12 (27%) |
Note: Values in bold signify p-values that meet the significance threshold of P < .05, 2-sided. Values in italics indicate the no. (%) of patients with missing data for the variable indicated.